Table 1 Baseline characteristics of study participants

Age (years)^*

7 (5–10)

7 (5–11)

7 (5.5-9)

0.961

Male sex^#

82 (65.1%)

44 (63.8%)

38 (66.7%)

0.734

Body mass index (kg/m²)^$

16.5 (2.89)

16.5 (3.25)

16.6 (2.41)

0.777

Head circumference (cm)^$

50.4 (1.30)

50.3 (1.42)

50.6 (1.13)

0.225

Urban residence^#

32 (25.4%)

16 (23.2%)

16 (28.1%)

0.531

Low socioeconomic level^#

71 (56.4)

39 (56.5%)

32 (56.1%)

0.966

Low parental education^#

88 (69.8%)

49 (71.0%)

39 (68.4%)

0.752

Parental work^#

0.195

 None

17 (13.5%)

10 (14.5%)

7 (12.3%)

 Government

62 (49.2%)

29 (42.0%)

33 (57.9%)

 Private

47 (37.3%)

30 (43.5%)

17 (29.8%)

Parental consanguinity^#

85 (67.5%)

43 (62.3%)

42 (73.7%)

0.175

Family history of epilepsy^#

26 (20.6%)

16 (23.2%)

10 (17.5%)

0.436

Gastrointestinal manifestations^#

61 (48.4%)

32 (46.4%)

29 (50.9%)

0.615

Seizures, generalized tonic-clonic/absence

117/9

63/6

54/3

0.511

Seizure frequency per month^*

5 (3–6)

5 (3–6)

4 (3–6)

0.813

Status epilepticus in last 2 months^#

22 (17.5%)

12 (17.4%)

10 (17.5%)

0.982

Anti-seizure medication^#

 Levetiracetam

126 (100%)

69 (100%)

57 (100%)

NA

 Sodium valproate

124 (98.4%)

68 (98.6%)

56 (98.3%)

1.000

 Topiramate

66 (52.4%)

34 (49.3%)

32 (56.1%)

0.443

 Clonazepam

31 (24.6%)

18 (26.1%)

13 (22.8%)

0.670